The UPMC Hillman Cancer Center Immunologic Monitoring and Cellular Products Laboratory (IMCPL) is responsible for therapeutic cell product generation (CPL), serial monitoring of immunologic functions (IML) in patients with cancer who are treated with biologic therapies, and banking of blood and tissues for patients on clinical protocols (TPF). The IMCPL plays a critical role in supporting novel investigator-initiated immunotherapy trials at UPMC Hillman Cancer Center.
